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ABSTRACT
Background and Objectives: Geographic distribution of hypertension management in Korea 
has never been reported. We investigated temporal and regional trends of hypertension 
management in Korea.
Methods: For each calendar year from 2002 to 2016, we identified 2,423,245 to 7,549,989 
persons aged ≥30 years treated for hypertension (total 80,564,109 cases). We calculated 
yearly age-sex standardized rates for medication adherence, combination therapy, blood 
test, and urine test according to geographic regions. We then used multivariate logistic 
regression to calculate odds ratios for hypertension management adjusted for individual-level 
sociodemographic factors.
Results: Adherence rates have markedly increased from 24.4% (2002) to 71.6% (2016) 
nationwide. Regional difference was prominent in 2002 (highest, 31.7% in Seoul; lowest, 
14.4% in Jeonbuk), but has become less noticeable over 15 years (highest, 73.1% in Daejeon; 
lowest, 69.0% in Jeonnam, 2016). Combination therapy rates increased from 42.8% (2002) 
to 61.0% (2011), but are in decreasing trend after 2011. Blood test rates were 58.8% in 2016, 
whereas urine test rates have been stagnant below 50% across all regions. Geographic 
variations of combination therapy and complication screening rates were not profound. 
Results from multivariable logistic regression, adjusted for age and sex, were in agreement 
with trends observed by standardized rates. The odds ratios remained unchanged when the 
models were further adjusted for employment status and household income.
Conclusions: Regional difference in hypertension management was evident in the past, but 
has become less apparent over the last 15 years in Korea.
Keywords: Hypertension; Medication adherence; Spatio-temporal analysis
INTRODUCTION
Hypertension is a major risk factor for cardiovascular morbidity and mortality worldwide.1) 
Although effective blood pressure (BP)-lowering medications have been developed, 
awareness and control for hypertension often differ by various sociodemographic factors.2-4) 
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In particular, geographic variations have been reported for hypertension prevalence and 
management in both high- and low-resource settings.5-10) However, determinants for regional 
health disparity remains poorly understood.
In South Korea, National Health Insurance Service (NHIS) is the single provider of universal 
and compulsory healthcare coverage. Per capita doctor visits in Korea is the highest 
among OECD countries,11) and national health screening is widely provided, with high 
participation rate (77.7% in 2016).12) Therefore, health disparity in Korea is expected to be 
less pronounced than in other high-income countries. The Korean Society of Hypertension 
reported overall increasing trend of diagnosis and treatment for hypertension over the last 15 
years.13) However, geographic distribution of hypertension management in Korea has never 
been reported. We thus investigated the temporal and geospatial pattern of hypertension 
management in Korea, including medication adherence, use of combination therapy, and 
screening tests for complication.
METHODS
Data source
We constructed a nationwide repeated cross-sectional dataset of calendar years 2002 
to 2016 from the NHIS database, which includes de-identified records of the entire 
Korean population. NHIS offers National Health Insurance (NHI) program for 97% of the 
population, and Medical Aid for the remaining 3% with financial needs or under special 
provision (e.g., national meritorious persons). The NHIS database contains claims and 
diagnoses, coded with International Classification of Disease, 10th edition (ICD-10), as well 
as individual-level sociodemographic details, including residential area.14) The study protocol 
was approved by the Institutional Review Board of Severance Hospital, Yonsei University 
Health System, Seoul, Korea (approval No. 4-2017-0322), and the requirement for informed 
consent was waived.
Study population
For each calendar year, we identified all individuals, aged 30 years or more, claimed for 
primary hypertension (ICD-10: I10) and antihypertensive medication (Supplementary 
Table 1). We excluded persons with incomplete geographic, sociodemographic, or hospital 
information—e.g., foreigners, military personnel, Medical Aid beneficiaries, etc. The same 
individual could be included in multiple calendar years, but would contribute only one 
observation per year included. The final dataset included a total of 80,564,109 observations 
(2,423,245 to 7,549,989 persons in 2002 to 2016), and the population size in each calendar 
year are summarized in Supplementary Table 2.
Regional and sociodemographic information
There are 8 metropolitan cities (Seoul, Busan, Daegu, Incheon, Gwangju, Daejeon, Ulsan, 
and Sejong) and 9 provinces (Gyeonggi, Gangwon, Chungbuk, Chungnam, Jeonbuk, 
Jeonnam, Gyeongbuk, Gyeongnam, and Jeju) in South Korea. For analytical purpose, we 
merged Sejong city with Chungnam province, since Sejong was named a metropolitan city 
only after 2012. Seoul is the capital city; together with adjacent regions, Seoul, Incheon, 
and Gyeonggi are considered capital area. Metropolitan cities and provinces comprise 
municipal divisions: si, gun, or gu. Further submunicipal divisions include dong as a unit 
of urban area; and eup - myeon - ri as units of rural area. For each individual, urbanization 
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level of residential area was categorized as metropolitan, urban, or rural according to the 
aforesaid regional units. Working status was categorized into either employed or self-/
non-employed. As a proxy for household income, we used insurance premium, determined 
by salary and asset information. We classified household income into quartiles, excluding 
Medical Aid.
Indicators of hypertension management
Quality of hypertension management was assessed for each calendar year. We used three 
indicators—adherence rate, combination therapy rate, and complication screening rate—
each of which was calculated as percentage among treated patients. Adherence to treatment 
was defined as being prescribed antihypertensive medication for ≥290 days (80%) in a given 
year. Presence of multiple antihypertensive classes in a single prescription was regarded as 
combination therapy. Identification of antihypertensive regimen, duration, and the hospital 
prescribing the medication followed the protocol developed for the Korea Hypertension 
Fact Sheet.13) Complication screening rates were calculated for blood chemistry (as serum 
creatinine test) and proteinuria test (as random urinalysis and/or urine microalbumin test), 
separately. Presence of at least one claim for a particular test was considered screened in a 
given year.
Statistical analysis
Population characteristics were reported as frequency and percentage, or median and 
interquartile range. For each calendar year, hypertension management rates were directly 
age-sex standardized to the 2016 population. We chose four representative years of 4- or 
5-year intervals (2002, 2006, 2011, and 2016), and visualized the geographic distribution of 
hypertension management on a map. We then used logistic regression to calculate odds ratio 
(OR) and 95% confidence interval (CI), for each indicator of hypertension management, 
according to geographic region and urbanization level, in each representative year. 
Multivariable logistic model was adjusted for age, sex, employment status, and household 
income quartiles. All analyses were performed using SAS version 9.4 (SAS Institute Inc., 
Cary, NC, USA) and R version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria; 
http://www.R-project.org).
RESULTS
Subject characteristics
In 2002, a total of 2,423,245 individuals were treated for hypertension, and the number of 
treated patients gradually increased, reaching 7,549,989 in 2016 (Table 1). The proportion of 
male sex and employed workers among treated patients increased over time. The geographic 
distribution of patients remained largely unchanged, but an increasing proportion of 
patients living in non-metropolitan urban areas was observed. Regarding antihypertensive 
drug classes, the use of angiotensin II receptor blockers abruptly increased, from 12.9% in 
2002 to 68.6% in 2016, while the use of beta-blockers or angiotensin-converting-enzyme 
(ACE) inhibitors declined over time. The percentage of dual therapy continuously increased, 
whereas the percentage of using 3 or more classes peaked at 2011 (20.1%) and started 
decreasing. The proportion of patients adherent to antihypertensive treatment was 24.3% in 
2002, but markedly increased reaching 71.6% in 2016. The proportion of patients screened 
for complications also increased over time, although not dramatically.
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Table 1. Population characteristics by calendar year
Variables Year
2002 (n=2,423,245) 2006 (n=4,466,235) 2011 (n=6,155,625) 2016 (n=7,549,989)
Age, years 60 (51–68) 61 (51–69) 62 (53–71) 63 (54–73)
Sex
Female 1,418,840 (58.6) 2,436,318 (54.5) 3,200,523 (52.0) 3,764,676 (49.9)
Male 1,004,405 (41.4) 2,029,917 (45.5) 2,955,102 (48.0) 3,785,313 (50.1)
Employment status
Employed 328,602 (13.6) 724,638 (16.2) 1,256,082 (20.4) 1,888,291 (25.0)
Self- or non-employed 2,094,643 (86.4) 3,741,597 (83.8) 4,899,543 (79.6) 5,661,698 (75.0)
Household income, quartile
Q4, highest 946,513 (39.1) 1,652,681 (37.0) 2,387,228 (38.8) 2,887,231 (38.2)
Q3 575,664 (23.8) 1,112,429 (24.9) 1,503,730 (24.4) 1,816,233 (24.1)
Q2 477,076 (19.7) 862,046 (19.3) 1,112,297 (18.1) 1,387,833 (18.4)
Q1, lowest 423,992 (17.5) 839,079 (18.8) 1,152,370 (18.7) 1,458,692 (19.3)
Capital region
Capital* 1,143,339 (47.2) 2,121,397 (47.5) 2,946,116 (47.9) 3,610,290 (47.8)
Non-capital 1,279,906 (52.8) 2,344,838 (52.5) 3,209,509 (52.1) 3,939,699 (52.2)
Urbanization level
Metropolitan 1,111,036 (45.8) 1,983,742 (44.4) 2,651,916 (43.1) 3,183,798 (42.2)
Urban 727,167 (30.0) 1,386,002 (31.0) 2,005,339 (32.6) 2,577,882 (34.1)
Rural 585,042 (24.1) 1,096,491 (24.6) 1,498,370 (24.3) 1,788,309 (23.7)
Region
Seoul 538,731 (22.2) 958,766 (21.5) 1,260,692 (20.5) 1,470,947 (19.5)
Busan 187,086 (7.7) 340,847 (7.6) 443,725 (7.2) 522,213 (6.9)
Daegu 111,261 (4.6) 196,515 (4.4) 268,634 (4.4) 336,191 (4.5)
Incheon 125,777 (5.2) 229,109 (5.1) 326,459 (5.3) 415,602 (5.5)
Gwangju 59,044 (2.4) 104,185 (2.3) 140,890 (2.3) 173,855 (2.3)
Daejeon 71,918 (3.0) 123,265 (2.8) 166,826 (2.7) 201,390 (2.7)
Ulsan 42,107 (1.7) 78,888 (1.8) 117,668 (1.9) 151,734 (2.0)
Gyeonggi 478,831 (19.8) 933,522 (20.9) 1,358,965 (22.1) 1,723,741 (22.8)
Gangwon 86,182 (3.6) 169,876 (3.8) 227,098 (3.7) 277,169 (3.7)
Chungbuk 82,826 (3.4) 148,128 (3.3) 201,744 (3.3) 248,007 (3.3)
Chungnam (and Sejong) 116,110 (4.8) 218,085 (4.9) 301,572 (4.9) 377,893 (5.0)
Jeonbuk 112,747 (4.7) 193,181 (4.3) 254,919 (4.1) 314,254 (4.2)
Jeonnam 117,714 (4.9) 209,092 (4.7) 275,707 (4.5) 330,514 (4.4)
Gyeongbuk 135,450 (5.6) 259,284 (5.8) 353,878 (5.7) 441,950 (5.9)
Gyeongnam 143,600 (5.9) 272,791 (6.1) 388,109 (6.3) 475,001 (6.3)
Jeju 13,861 (0.6) 30,701 (0.7) 68,739 (1.1) 89,528 (1.2)
Hospital type
Tertiary 399,544 (16.5) 544,110 (12.2) 653,774 (10.6) 846,148 (11.2)
Secondary 352,815 (14.6) 888,229 (19.9) 1,284,624 (20.9) 1,602,524 (21.2)
Primary 1,670,886 (69.0) 3,033,896 (67.9) 4,217,227 (68.5) 5,101,317 (67.6)
Antihypertensive drug class†
Diuretics 699,054 (28.8) 1,752,408 (39.2) 2,359,952 (38.3) 2,160,891 (28.6)
Beta-blockers 828,571 (34.2) 1,357,803 (30.4) 1,347,608 (21.9) 1,265,299 (16.8)
Calcium channel blockers 1,366,749 (56.4) 2,824,514 (63.2) 3,779,920 (61.4) 4,498,709 (59.6)
ACE inhibitors 436,732 (18.0) 580,556 (13.0) 335,593 (5.5) 190,856 (2.5)
ARBs 312,966 (12.9) 1,215,366 (27.2) 3,456,875 (56.2) 5,180,084 (68.6)
Others 75,861 (3.1) 60,783 (1.4) 50,451 (0.8) 40,019 (0.5)
Number of drug classes
1 1,404,024 (57.9) 2,038,863 (45.7) 2,415,293 (39.2) 3,129,778 (41.5)
2 779,480 (32.2) 1,657,480 (37.1) 2,505,277 (40.7) 3,226,128 (42.7)
≥3 239,741 (9.9) 769,892 (17.2) 1,235,055 (20.1) 1,194,083 (15.8)
Adherent to treatment 587,932 (24.3) 2,254,101 (50.5) 4,057,044 (65.9) 5,406,003 (71.6)
Tested for serum creatinine 942,122 (38.9) 2,001,078 (44.8) 3,172,014 (51.5) 4,439,896 (58.8)
Tested for proteinuria 996,133 (41.1) 1,912,225 (42.8) 2,631,028 (42.7) 3,390,150 (44.9)
Data are presented as median (interquartile range) or frequency (percent).
ACE = angiotensin-converting-enzyme; ARB = angiotensin II receptor blocker.
*Capital region includes Seoul, Incheon, and Gyeonggi; †Counted with duplicates for combination therapy.
Management of hypertension by geographic region
Yearly standardized rates of adherence, combination therapy, and complication screening by 
capital/non-capital region or urbanization level are plotted in Figure 1. The same indicators 
in four representative years were map-visualized in Figure 2, and their numeric values 
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Figure 1. Age-sex standardized rates of hypertension management by regional characteristics and calendar year. All rates (%) are directly age-sex standardized 
to the 2016 population. (A, B) Adherence rates. (C, D) Combination therapy rates. (E, F) Blood test rates. (G, H) Urine test rates. (A, C, E, G) are stratified into 
capital or non-capital regions. (B, D, F, H) are stratified into metropolitan, urban, or rural area. (continued to the next page)
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Figure 2. Map visualization of hypertension management by geographic region and calendar year. Yearly rates of adherence, combination therapy, blood test, 
and urine test are directly age-sex standardized to the 2016 population. Fill colors represent rates in percent. Crude and standardized rates in numeric forms are 
available in Supplementary Tables 3-6. (continued to the next page)
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Figure 1. (Continued) Age-sex standardized rates of hypertension management by regional characteristics and calendar year. All rates (%) are directly age-sex 
standardized to the 2016 population. (A, B) Adherence rates. (C, D) Combination therapy rates. (E, F) Blood test rates. (G, H) Urine test rates. (A, C, E, G) are 
stratified into capital or non-capital regions. (B, D, F, H) are stratified into metropolitan, urban, or rural area.
are provided as supplements (Supplementary Tables 3-6). In 2002, age-sex standardized 
adherence rates were 29.1% in the capital region, and 28.2% in metropolitan cities (31.7% 
in Seoul, 27.6% in Daegu, descending), whereas adherence rates in rural areas, especially 
in the southern provinces, were below 20% (14.4% in Jeonbuk, 15.6% in Jeonnam, 18.6% 
in Gyeongnam, ascending). In 2006, adherence rate in Seoul reached 56.3%, but southern 
regions, including Jeonnam and Jeonbuk, showed adherence rates below 45%. By 2011, all 
regions reached adherence rates above 60%, and in 2016, above 65% (highest, 73.1% in 
Daejeon; lowest, 69.0% in Jeonnam).
Combination therapy and complication screening rates were less heterogeneous across 
regions. In 2002, the highest combination therapy rate was 48.6% in Busan, followed by 
46.4% in Gangwon, while the lowest rates were 37.0% in Jeonnam and 39.5% in Gwangju. By 
2011, most regions reached 60% combination therapy rate (highest, 64.6% in Gangwon), but 
the rates showed decreasing trend thereafter, especially in metropolitan cities (lowest, 56.5% 
in Seoul and Daegu, 2016). As for complication screening, blood test rates increased from 
39.3% to 58.8% nationwide, whereas urine test rates remained below 50% across all regions 
(lowest, 40.9% in Ulsan, 41.8% in Gyeongbuk, 2016).
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Figure 2. (Continued) Map visualization of hypertension management by geographic region and calendar year. Yearly rates of adherence, combination therapy, 
blood test, and urine test are directly age-sex standardized to the 2016 population. Fill colors represent rates in percent. Crude and standardized rates in 
numeric forms are available in Supplementary Tables 3-6.
When stratified by sex, women, especially those living in non-capital or rural area, 
had lower rates of hypertension management compared with men in 2002. However, 
adherence rate and complication screening rate in women exceeded those in men over time. 
Combination therapy rate, on the other hand, remained lower in women. The pattern of 
hypertension management according to regional characteristics were similar in both sexes 
(Supplementary Figure 1).
In multivariable logistic regression at individual level (Tables 2-5), the odds for being adherent 
to antihypertensive treatment in most provinces were less than 60% of that in Seoul, when 
adjusted for age and sex, in 2002 (lowest in Jeonbuk: OR, 0.36; 95% CI, 0.36–0.37; Table 2, 
model 1). However, the regional difference gradually diminished over time, arriving within 
20% in 2016 (highest in Daegu: OR, 1.06; 95% CI, 1.05–1.07 and lowest in Jeonnam: OR, 
0.86; 95% CI, 0.86–0.87; Table 2, model 1). Also, for combination therapy and complication 
screening, results from logistic regression were in agreement with our observations with 
age-sex standardized rates. Furthermore, for all indicators of hypertension management, the 
ORs remained largely unchanged, when the models were adjusted for employment status and 
household income (Tables 2-5, model 2).
Finally, as some patients may visit out-of-region hospitals, we also calculated adherence 
rate and combination therapy rate according to geographic region and characteristics of 
the hospital prescribing the medications (Supplementary Figures 2 and 3). The trend of 
hypertension management by region of hospital were largely similar to that by region of 
residence. When stratified by hospital type, adherence rate in primary clinics was lower 
than that in tertiary hospitals in 2002 (primary, 22.1%; tertiary, 36.6%), but the rate rapidly 
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Table 2. Adjusted odds ratios for medication adherence according to geographic region and calendar year
Variables Model 1 Model 2
2002 2006 2011 2016 2002 2006 2011 2016
Capital region
Capital* 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Non-capital 0.64 (0.64–0.65) 0.76 (0.76–0.76) 0.95 (0.94–0.95) 0.97 (0.97–0.97) 0.65 (0.65–0.66) 0.77 (0.76–0.77) 0.95 (0.95–0.95) 0.98 (0.97–0.98)
Urbanization level
Metropolitan 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Urban 0.82 (0.82–0.83) 0.94 (0.93–0.94) 1.00 (1.00–1.00) 1.01 (1.00–1.01) 0.82 (0.82–0.83) 0.94 (0.93–0.94) 1.00 (1.00–1.00) 1.00 (1.00–1.01)
Rural 0.56 (0.55–0.56) 0.76 (0.76–0.76) 0.90 (0.90–0.91) 0.94 (0.94–0.95) 0.57 (0.57–0.58) 0.77 (0.77–0.78) 0.91 (0.91–0.92) 0.95 (0.95–0.96)
Region
Seoul 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Busan 0.68 (0.68–0.69) 0.79 (0.78–0.80) 0.99 (0.98–1.00) 0.96 (0.95–0.97) 0.70 (0.69–0.70) 0.80 (0.79–0.80) 0.99 (0.99–1.00) 0.96 (0.95–0.97)
Daegu 0.83 (0.82–0.84) 0.88 (0.87–0.88) 1.05 (1.04–1.06) 1.06 (1.05–1.07) 0.84 (0.83–0.85) 0.88 (0.87–0.89) 1.06 (1.05–1.07) 1.07 (1.06–1.08)
Incheon 0.74 (0.73–0.75) 0.81 (0.80–0.82) 0.97 (0.96–0.97) 1.01 (1.00–1.02) 0.76 (0.74–0.76) 0.82 (0.81–0.83) 0.97 (0.96–0.98) 1.01 (1.00–1.02)
Gwangju 0.60 (0.59–0.62) 0.62 (0.61–0.62) 0.84 (0.84–0.85) 0.88 (0.87–0.89) 0.60 (0.59–0.62) 0.62 (0.61–0.62) 0.85 (0.84–0.86) 0.88 (0.87–0.89)
Daejeon 0.77 (0.76–0.78) 0.88 (0.86–0.88) 1.03 (1.02–1.04) 1.06 (1.05–1.07) 0.77 (0.76–0.79) 0.88 (0.86–0.88) 1.03 (1.02–1.05) 1.06 (1.05–1.07)
Ulsan 0.53 (0.52–0.54) 0.73 (0.72–0.74) 1.00 (0.99–1.01) 1.00 (0.98–1.01) 0.52 (0.51–0.54) 0.72 (0.71–0.73) 0.99 (0.98–1.00) 0.99 (0.98–1.00)
Gyeonggi 0.79 (0.78–0.80) 0.91 (0.91–0.92) 1.00 (1.00–1.01) 1.00 (1.00–1.01) 0.80 (0.79–0.81) 0.92 (0.91–0.92) 1.00 (1.00–1.01) 1.00 (1.00–1.00)
Gangwon 0.61 (0.60–0.62) 0.81 (0.80–0.82) 0.97 (0.96–0.98) 1.04 (1.03–1.05) 0.63 (0.62–0.64) 0.82 (0.81–0.83) 0.98 (0.97–0.98) 1.05 (1.04–1.06)
Chungbuk 0.58 (0.57–0.59) 0.77 (0.76–0.78) 0.98 (0.97–0.99) 1.00 (0.99–1.01) 0.59 (0.58–0.60) 0.78 (0.77–0.78) 0.98 (0.97–0.99) 1.00 (0.99–1.01)
Chungnam† 0.49 (0.49–0.50) 0.72 (0.71–0.72) 0.95 (0.94–0.96) 0.97 (0.96–0.98) 0.51 (0.50–0.52) 0.73 (0.72–0.73) 0.95 (0.94–0.96) 0.97 (0.97–0.98)
Jeonbuk 0.36 (0.36–0.37) 0.56 (0.55–0.56) 0.86 (0.85–0.87) 0.94 (0.93–0.95) 0.37 (0.36–0.38) 0.56 (0.56–0.57) 0.87 (0.86–0.88) 0.95 (0.94–0.96)
Jeonnam 0.40 (0.39–0.40) 0.53 (0.53–0.54) 0.77 (0.77–0.78) 0.86 (0.86–0.87) 0.41 (0.40–0.42) 0.54 (0.54–0.55) 0.78 (0.78–0.79) 0.87 (0.86–0.88)
Gyeongbuk 0.53 (0.53–0.54) 0.70 (0.69–0.71) 0.94 (0.93–0.95) 0.99 (0.98–1.00) 0.54 (0.54–0.55) 0.71 (0.70–0.71) 0.95 (0.94–0.95) 1.00 (0.99–1.01)
Gyeongnam 0.50 (0.50–0.51) 0.71 (0.70–0.72) 0.96 (0.95–0.96) 0.95 (0.94–0.96) 0.51 (0.51–0.52) 0.71 (0.71–0.72) 0.96 (0.95–0.97) 0.95 (0.94–0.96)
Jeju 0.60 (0.57–0.62) 0.78 (0.76–0.80) 1.00 (0.98–1.02) 0.98 (0.97–1.00) 0.60 (0.58–0.62) 0.78 (0.76–0.80) 1.01 (0.99–1.03) 0.99 (0.98–1.00)
All values are reported as odds ratios (and 95% confidence intervals). Model 1 was adjusted for age and sex. Model 2 was further adjusted for employment 
status and income quartiles.
*Capital region includes Seoul, Incheon, and Gyeonggi; †Sejong was merged with Chungnam.
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Table 3. Adjusted odds ratios for combination therapy according to geographic region and calendar year
Variables Model 1 Model 2
2002 2006 2011 2016 2002 2006 2011 2016
Capital region
Capital* 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Non-capital 0.97 (0.97–0.98) 1.02 (1.02–1.02) 1.03 (1.03–1.03) 1.07 (1.06–1.07) 0.97 (0.97–0.98) 1.02 (1.02–1.02) 1.03 (1.02–1.03) 1.06 (1.06–1.07)
Urbanization level
Metropolitan 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Urban 0.97 (0.96–0.97) 1.00 (0.99–1.00) 1.02 (1.01–1.02) 1.05 (1.04–1.05) 0.97 (0.96–0.97) 1.00 (0.99–1.00) 1.02 (1.01–1.02) 1.05 (1.04–1.05)
Rural 0.86 (0.86–0.87) 0.97 (0.97–0.98) 1.04 (1.03–1.04) 1.11 (1.11–1.12) 0.86 (0.86–0.87) 0.97 (0.97–0.98) 1.03 (1.03–1.04) 1.11 (1.10–1.11)
Region
Seoul 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Busan 1.21 (1.20–1.22) 1.23 (1.22–1.24) 1.19 (1.18–1.20) 1.18 (1.17–1.19) 1.21 (1.19–1.22) 1.22 (1.21–1.23) 1.18 (1.17–1.19) 1.17 (1.17–1.18)
Daegu 0.94 (0.92–0.95) 0.97 (0.96–0.98) 0.96 (0.95–0.96) 1.00 (1.00–1.01) 0.94 (0.92–0.95) 0.96 (0.96–0.98) 0.95 (0.94–0.96) 1.00 (0.99–1.01)
Incheon 0.96 (0.94–0.97) 1.04 (1.03–1.05) 1.09 (1.09–1.10) 1.12 (1.11–1.13) 0.95 (0.94–0.96) 1.04 (1.03–1.05) 1.09 (1.08–1.10) 1.12 (1.11–1.12)
Gwangju 0.84 (0.82–0.85) 0.97 (0.96–0.98) 1.00 (0.99–1.01) 1.03 (1.02–1.04) 0.84 (0.82–0.85) 0.97 (0.96–0.98) 1.00 (0.99–1.01) 1.03 (1.02–1.04)
Daejeon 0.90 (0.88–0.91) 0.99 (0.98–1.00) 1.02 (1.01–1.03) 1.05 (1.04–1.06) 0.90 (0.88–0.91) 0.99 (0.98–1.00) 1.02 (1.01–1.03) 1.04 (1.04–1.05)
Ulsan 1.03 (1.01–1.05) 1.11 (1.09–1.13) 1.16 (1.14–1.17) 1.12 (1.10–1.13) 1.03 (1.01–1.05) 1.12 (1.10–1.13) 1.17 (1.15–1.18) 1.13 (1.12–1.14)
Gyeonggi 0.95 (0.94–0.96) 1.03 (1.03–1.04) 1.06 (1.06–1.07) 1.09 (1.09–1.10) 0.95 (0.94–0.96) 1.03 (1.02–1.04) 1.06 (1.05–1.07) 1.09 (1.08–1.09)
Gangwon 1.12 (1.10–1.13) 1.20 (1.19–1.21) 1.23 (1.22–1.24) 1.27 (1.26–1.28) 1.11 (1.10–1.13) 1.19 (1.18–1.21) 1.23 (1.21–1.24) 1.26 (1.25–1.27)
Chungbuk 0.94 (0.93–0.96) 1.00 (0.99–1.01) 1.07 (1.06–1.08) 1.17 (1.16–1.18) 0.94 (0.93–0.96) 0.99 (0.98–1.00) 1.06 (1.05–1.07) 1.16 (1.15–1.17)
Chungnam† 0.85 (0.84–0.86) 1.02 (1.01–1.03) 1.12 (1.11–1.13) 1.16 (1.15–1.17) 0.85 (0.84–0.86) 1.02 (1.01–1.03) 1.12 (1.11–1.13) 1.16 (1.15–1.16)
Jeonbuk 0.88 (0.87–0.90) 1.00 (0.99–1.01) 1.00 (1.00–1.01) 1.12 (1.11–1.13) 0.88 (0.87–0.89) 1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.11 (1.11–1.12)
Jeonnam 0.76 (0.74–0.76) 0.91 (0.90–0.92) 1.01 (1.00–1.02) 1.16 (1.15–1.17) 0.75 (0.74–0.76) 0.90 (0.89–0.91) 1.01 (1.00–1.01) 1.15 (1.14–1.16)
Gyeongbuk 0.86 (0.85–0.87) 1.00 (0.99–1.01) 1.01 (1.01–1.02) 1.08 (1.08–1.09) 0.86 (0.85–0.87) 1.00 (0.99–1.01) 1.01 (1.00–1.02) 1.08 (1.07–1.09)
Gyeongnam 1.01 (1.00–1.02) 1.04 (1.03–1.05) 1.07 (1.07–1.08) 1.14 (1.13–1.15) 1.01 (1.00–1.02) 1.04 (1.03–1.05) 1.07 (1.06–1.08) 1.14 (1.13–1.15)
Jeju 0.87 (0.84–0.90) 0.99 (0.97–1.01) 1.00 (0.99–1.02) 1.10 (1.08–1.12) 0.87 (0.84–0.90) 0.99 (0.97–1.01) 1.00 (0.98–1.01) 1.09 (1.08–1.11)
All values are reported as odds ratios (and 95% confidence intervals). Model 1 was adjusted for age and sex. Model 2 was further adjusted for employment 
status and income quartiles.
*Capital region includes Seoul, Incheon, and Gyeonggi; †Sejong was merged with Chungnam.
Table 4. Adjusted odds ratios for blood test according to geographic region and calendar year
Variables Model 1 Model 2
2002 2006 2011 2016 2002 2006 2011 2016
Capital region
Capital* 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Non-capital 0.76 (0.75–0.76) 0.86 (0.85–0.86) 0.86 (0.86–0.86) 0.91 (0.90–0.91) 0.76 (0.75–0.76) 0.85 (0.85–0.86) 0.86 (0.85–0.86) 0.90 (0.90–0.90)
Urbanization level
Metropolitan 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Urban 0.93 (0.92–0.94) 0.99 (0.99–1.00) 0.99 (0.99–1.00) 1.02 (1.02–1.03) 0.93 (0.92–0.94) 0.99 (0.99–1.00) 0.99 (0.99–1.00) 1.03 (1.02–1.03)
Rural 0.80 (0.80–0.81) 0.87 (0.86–0.87) 0.93 (0.93–0.94) 0.98 (0.98–0.98) 0.80 (0.80–0.81) 0.86 (0.86–0.87) 0.92 (0.92–0.93) 0.97 (0.97–0.97)
Region
Seoul 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Busan 0.64 (0.64–0.65) 0.78 (0.78–0.79) 0.75 (0.74–0.75) 0.83 (0.82–0.83) 0.65 (0.64–0.66) 0.79 (0.78–0.80) 0.75 (0.74–0.75) 0.82 (0.82–0.83)
Daegu 0.65 (0.64–0.66) 0.81 (0.80–0.82) 0.77 (0.76–0.77) 0.84 (0.83–0.84) 0.65 (0.64–0.66) 0.81 (0.80–0.82) 0.76 (0.76–0.77) 0.83 (0.82–0.84)
Incheon 0.73 (0.72–0.74) 0.84 (0.84–0.85) 0.91 (0.90–0.92) 0.90 (0.90–0.91) 0.74 (0.73–0.75) 0.85 (0.85–0.86) 0.91 (0.91–0.92) 0.90 (0.90–0.91)
Gwangju 0.78 (0.76–0.79) 0.92 (0.91–0.93) 0.88 (0.87–0.89) 0.93 (0.92–0.94) 0.77 (0.76–0.79) 0.92 (0.91–0.93) 0.88 (0.87–0.89) 0.92 (0.92–0.93)
Daejeon 0.72 (0.71–0.73) 0.86 (0.86–0.88) 0.76 (0.75–0.77) 0.73 (0.72–0.74) 0.72 (0.71–0.73) 0.86 (0.86–0.88) 0.76 (0.75–0.77) 0.73 (0.72–0.74)
Ulsan 0.69 (0.68–0.70) 0.76 (0.75–0.77) 0.77 (0.76–0.78) 0.84 (0.83–0.85) 0.69 (0.68–0.71) 0.76 (0.75–0.77) 0.76 (0.75–0.77) 0.83 (0.82–0.84)
Gyeonggi 0.82 (0.81–0.83) 0.92 (0.92–0.92) 0.90 (0.90–0.91) 0.95 (0.94–0.95) 0.82 (0.82–0.83) 0.92 (0.92–0.93) 0.91 (0.90–0.91) 0.95 (0.95–0.96)
Gangwon 0.84 (0.83–0.85) 0.86 (0.85–0.87) 0.93 (0.92–0.94) 1.04 (1.03–1.05) 0.84 (0.83–0.86) 0.86 (0.85–0.87) 0.92 (0.92–0.93) 1.04 (1.03–1.04)
Chungbuk 0.61 (0.60–0.62) 0.75 (0.74–0.76) 0.80 (0.79–0.81) 0.90 (0.89–0.91) 0.62 (0.61–0.63) 0.75 (0.74–0.76) 0.80 (0.79–0.81) 0.90 (0.89–0.90)
Chungnam† 0.70 (0.70–0.71) 0.84 (0.83–0.85) 0.87 (0.87–0.88) 0.89 (0.88–0.90) 0.71 (0.70–0.72) 0.84 (0.83–0.85) 0.87 (0.86–0.88) 0.88 (0.87–0.89)
Jeonbuk 0.70 (0.69–0.71) 0.75 (0.74–0.76) 0.79 (0.78–0.79) 0.85 (0.85–0.86) 0.70 (0.69–0.71) 0.75 (0.74–0.76) 0.78 (0.78–0.79) 0.84 (0.84–0.85)
Jeonnam 0.61 (0.60–0.62) 0.82 (0.81–0.82) 0.83 (0.83–0.84) 0.88 (0.87–0.88) 0.61 (0.60–0.62) 0.82 (0.81–0.82) 0.83 (0.82–0.83) 0.87 (0.86–0.87)
Gyeongbuk 0.66 (0.65–0.67) 0.75 (0.74–0.75) 0.78 (0.77–0.78) 0.84 (0.84–0.85) 0.66 (0.65–0.67) 0.75 (0.74–0.75) 0.77 (0.77–0.78) 0.83 (0.83–0.84)
Gyeongnam 0.61 (0.60–0.62) 0.84 (0.83–0.84) 0.83 (0.82–0.84) 0.90 (0.90–0.91) 0.62 (0.61–0.62) 0.84 (0.83–0.84) 0.82 (0.82–0.83) 0.90 (0.89–0.90)
Jeju 0.77 (0.74–0.80) 1.16 (1.14–1.19) 1.07 (1.05–1.08) 1.10 (1.08–1.11) 0.77 (0.74–0.80) 1.16 (1.13–1.19) 1.06 (1.04–1.08) 1.09 (1.07–1.10)
All values are reported as odds ratios (and 95% confidence intervals). Model 1 was adjusted for age and sex. Model 2 was further adjusted for employment 
status and income quartiles.
*Capital region includes Seoul, Incheon, and Gyeonggi; †Sejong was merged with Chungnam.
improved and exceeded that of tertiary hospitals in 2008 and thereafter (primary, 74.7%; 
tertiary, 70.1%; in 2016). In case of combination therapy rate, the overall trend of rise and 
fall was observed in all three hospital types, but the decline after 2011 was more rapid in 
secondary and tertiary hospitals than in primary clinics.
DISCUSSION
In this nationwide study of persons treated for hypertension in Korea, we observed a trend 
of diminishing regional variation in hypertension management from 2002 to 2016. The 
largest inter-regional difference in the OR for medication adherence decreased from 64% 
in 2002 to 20% in 2016; and for combination therapy, from 45% in 2002 to 27% in 2016. 
Geographic distributions of complication screening rates were less heterogeneous. Of note, 
this is the first study to describe regional difference of hypertension management in Korea. 
Given that the NHI was universally implemented by 1989, finding of such low adherence 
rates and large regional differences in the early 2000s is interesting, as is the rapid 
improvements made thereafter.
Adherence rates have substantially increased nationwide, reaching 70% in most regions by 
2013. On the other hand, the recent decreasing trend of combination therapy rate is quite 
unexpected. While dual therapy rates are constantly increasing, triple (or higher) therapy 
rates have been slowly decreasing across all regions after 2011. As we do not have data on 
achieved BPs, it is unclear whether this trend reflects less intensive BP control, less need for 
triple therapy to achieve target BP, or a greater influx of new patients with initial single or 
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Table 5. Adjusted odds ratios for urine test according to geographic region and calendar year
Variables Model 1 Model 2
2002 2006 2011 2016 2002 2006 2011 2016
Capital region
Capital* 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Non-capital 0.92 (0.92–0.93) 0.92 (0.92–0.93) 0.92 (0.91–0.92) 0.93 (0.93–0.93) 0.92 (0.92–0.93) 0.92 (0.92–0.92) 0.91 (0.91–0.92) 0.92 (0.92–0.92)
Urbanization level
Metropolitan 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Urban 0.90 (0.90–0.91) 0.94 (0.93–0.94) 0.94 (0.94–0.94) 0.96 (0.96–0.96) 0.90 (0.90–0.91) 0.94 (0.93–0.94) 0.94 (0.94–0.94) 0.96 (0.96–0.96)
Rural 0.80 (0.80–0.81) 0.83 (0.83–0.84) 0.88 (0.88–0.89) 0.91 (0.91–0.92) 0.80 (0.79–0.80) 0.83 (0.83–0.84) 0.88 (0.87–0.88) 0.91 (0.90–0.91)
Region
Seoul 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Busan 0.85 (0.84–0.86) 0.91 (0.90–0.92) 0.89 (0.89–0.90) 0.93 (0.92–0.94) 0.85 (0.84–0.86) 0.91 (0.91–0.92) 0.89 (0.89–0.90) 0.93 (0.92–0.93)
Daegu 0.91 (0.90–0.92) 0.98 (0.97–0.99) 0.91 (0.90–0.91) 0.89 (0.88–0.90) 0.91 (0.90–0.92) 0.98 (0.97–0.99) 0.90 (0.90–0.91) 0.88 (0.88–0.89)
Incheon 0.86 (0.85–0.87) 0.92 (0.91–0.92) 0.96 (0.95–0.97) 0.98 (0.98–0.99) 0.87 (0.86–0.88) 0.92 (0.92–0.93) 0.96 (0.96–0.97) 0.98 (0.98–0.99)
Gwangju 1.14 (1.12–1.16) 1.09 (1.08–1.11) 1.03 (1.02–1.04) 1.07 (1.05–1.08) 1.14 (1.12–1.16) 1.09 (1.08–1.11) 1.03 (1.02–1.04) 1.06 (1.05–1.07)
Daejeon 0.89 (0.88–0.90) 0.97 (0.96–0.98) 0.86 (0.85–0.87) 0.88 (0.87–0.89) 0.89 (0.88–0.90) 0.97 (0.96–0.99) 0.86 (0.85–0.87) 0.88 (0.87–0.89)
Ulsan 0.81 (0.80–0.83) 0.84 (0.82–0.85) 0.78 (0.77–0.79) 0.78 (0.78–0.79) 0.82 (0.80–0.83) 0.84 (0.82–0.85) 0.78 (0.77–0.79) 0.78 (0.77–0.79)
Gyeonggi 0.82 (0.82–0.83) 0.91 (0.90–0.91) 0.90 (0.90–0.90) 0.93 (0.93–0.94) 0.83 (0.82–0.83) 0.91 (0.91–0.92) 0.90 (0.90–0.90) 0.93 (0.93–0.94)
Gangwon 0.82 (0.80–0.83) 0.82 (0.81–0.82) 0.86 (0.86–0.87) 0.89 (0.88–0.89) 0.81 (0.80–0.83) 0.82 (0.81–0.83) 0.86 (0.85–0.87) 0.88 (0.87–0.89)
Chungbuk 0.74 (0.73–0.75) 0.77 (0.76–0.78) 0.81 (0.80–0.82) 0.85 (0.85–0.86) 0.74 (0.73–0.75) 0.78 (0.77–0.78) 0.81 (0.80–0.81) 0.85 (0.84–0.86)
Chungnam† 0.82 (0.81–0.84) 0.84 (0.83–0.84) 0.86 (0.85–0.86) 0.89 (0.88–0.90) 0.82 (0.81–0.84) 0.84 (0.83–0.84) 0.85 (0.84–0.86) 0.88 (0.88–0.89)
Jeonbuk 0.95 (0.94–0.96) 0.93 (0.92–0.94) 0.94 (0.93–0.95) 0.99 (0.98–1.00) 0.95 (0.94–0.96) 0.93 (0.92–0.94) 0.93 (0.93–0.94) 0.98 (0.97–0.99)
Jeonnam 0.80 (0.80–0.82) 0.89 (0.88–0.90) 0.90 (0.90–0.91) 0.93 (0.92–0.94) 0.80 (0.79–0.82) 0.89 (0.88–0.90) 0.90 (0.89–0.91) 0.92 (0.91–0.93)
Gyeongbuk 0.80 (0.79–0.81) 0.79 (0.79–0.80) 0.80 (0.79–0.80) 0.82 (0.81–0.82) 0.80 (0.79–0.81) 0.79 (0.79–0.80) 0.79 (0.79–0.80) 0.81 (0.80–0.81)
Gyeongnam 0.70 (0.69–0.71) 0.82 (0.81–0.82) 0.82 (0.82–0.83) 0.85 (0.85–0.86) 0.70 (0.69–0.71) 0.82 (0.81–0.82) 0.82 (0.82–0.83) 0.85 (0.84–0.85)
Jeju 0.82 (0.80–0.85) 1.01 (0.99–1.04) 0.99 (0.97–1.00) 1.10 (1.09–1.12) 0.82 (0.79–0.85) 1.01 (0.99–1.03) 0.98 (0.96–1.00) 1.10 (1.08–1.11)
All values are reported as odds ratios (and 95% confidence intervals). Model 1 was adjusted for age and sex. Model 2 was further adjusted for employment 
status and income quartiles.
*Capital region includes Seoul, Incheon, and Gyeonggi; †Sejong was merged with Chungnam.
dual therapy. In the Korean National Health and Nutrition Examination Survey (KNHANES), 
1998–2016, the rate of BP control below 140/90 mmHg have plateaued at 70% among treated 
patients after 2010.13) However, information on antihypertensive regimen was not available 
in KNHANES. In the early- to mid-2010s, results from the Action to Control Cardiovascular 
Risk in Diabetes blood pressure (ACCORD BP) trial15) and the subsequent 2013 European 
Society of Hypertension (ESH)/European Society of Cardiology (ESC)16) and the 2014 Eighth 
Joint National Committee (JNC-8)17) hypertension guidelines de-emphasized the importance 
of intensive BP lowering. The impact of such guidelines may have been reflected in this 
decreasing trend of combination therapy after 2011, especially in secondary and tertiary 
hospitals. In this regard, it would be interesting to see the impact of Systolic Blood Pressure 
Intervention Trial (SPRINT)18) and the recent 2017 American College of Cardiology/American 
Heart Association19) and 2018 ESC/ESH20) guidelines on combination therapy rate in Korea in 
the near future.
For complication screening, The Korean Society of Hypertension recommends annual testing 
for proteinuria, and blood chemistry, including creatinine and electrolytes.21)22) Blood test 
rates have modestly improved, but still remains below 60% in most regions. Urine test rates 
have been stagnant below 50% across all regions. Particularly, urine microalbumin tests are 
done in less than 30%, with no improvement over 15 years. Measurement of random urine 
albumin-to-creatinine ratio, for screening glomerular injury, should be more advocated as 
per international guidelines.19)20)
The reason for regional variation in hypertension management is not entirely understood. 
A British study on hypertension treatment found attenuated regional effect when adjusted 
for sociodemographic factors including employment, education, etc.6) However, the 
study compared London with the rest of England, rather than inter-comparing regions or 
districts. Another study using small spatial units in Germany suggested areal deprivation to 
be associated with disease distribution.10) In our study, geographic effect on hypertension 
management remained unchanged, even after serial adjustment for individual-level 
sociodemographic variables, although lifestyle factors were not included in the model. In 
this regard, the large regional difference in the early 2000s, as well as its resolution, may be 
related to regional characteristics or infrastructures, rather than individual-level risk factors.
Our study has some notable strengths. Using a nationwide database of the entire Korean 
population, we captured nearly all cases of treated hypertension, providing representative 
indicators that may be useful for local governments and policymakers. Importantly, these 
indicators of hypertension management, as well as other covariates, were derived from 
objective data rather than self-report. Furthermore, individual-level data on residential 
areas, sociodemographic factors, and healthcare utilization were available. However, our 
study also has some limitations. First, diagnosis of hypertension was based on medical 
claims rather than clinical information. Definition of hypertension using administrative 
data has been well reviewed elsewhere.23) However, the true prevalence of hypertension 
cannot be determined, and individuals untreated or with no healthcare utilization would 
not be identified by claims data. Second, analyses on smaller regional units were not done. 
Aggregate figures are weighed more on populous subunits, and thus may underrepresent less 
inhabited areas. Using smaller areal units, with smoothing methods,24) would achieve a finer 
geospatial assessment, but would deviate from our purpose of providing useful indicators at 
provincial level. Third, in the logistic model, temporal and geospatial effects were analyzed 
separately rather than simultaneously. Therefore, inference on the change of geospatial effect 
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over time cannot be made, and would instead require a multilevel approach. Fourth, lifestyle 
factors and other unmeasured confounders may have contributed to geographic variations 
at individual level. Lastly, this study excluded Medical Aid beneficiaries, and thus should be 
interpreted accordingly.
In conclusion, geographic variation of hypertension management in Korea had been 
concerning, but the difference has become less apparent over the last 15 years. Adherence 
rates have plateaued above 70% nationwide. Recently decreasing trend of combination 
therapy rates should be noted, but its clinical implication is yet unclear. Finally, there is still 
room for improvement in complication screening, especially for proteinuria.
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